A trial looking at pembrolizumab for people with liver cancer (KEYNOTE-937)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Liver cancer

Status:

Open

Phase:

Phase 3

This trial is for people with cancer that started in the liver (primary liver cancer). It is for people who have had one of the following treatments to remove the cancer:

  • surgery 
  • heat directly to the tumour (tumour ablation) such as radiofrequency ablation or microwave ablation

More about this trial

The standard treatment for liver cancer that hasn’t spread to a distant part of the body, is surgery or treatment using heat to destroy cancer cells (tumour ablation). There are 2 types of tumour ablation for liver cancer:

  • radiofrequency ablation (RFA)
  • microwave ablation (MWA)

But sometimes liver cancer can come back after surgery or tumour ablation. Doctors in this trial, want to find out if a drug called pembrolizumab can help to stop liver cancer from coming back. 

Pembrolizumab (Keytruda) is a type of targeted drug called a monoclonal antibody. It targets and blocks the protein PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the immune system Open a glossary item to find and kill cancer cells. 

Everyone taking part in this trial has surgery or tumour ablation followed by pembrolizumab or a dummy drug (placebo). 

The main aim of this trial is to find out how well pembrolizumab works as an adjuvant treatment Open a glossary item for liver cancer. 
 

Who can enter

The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you. 

Who can take part
You may be able to join this trial if all of the following apply:

  • you have hepatocellular carcinoma (primary liver cancer) 
  • you have had surgery, radiofrequency ablation or microwave ablation to remove the cancer in the past 6 weeks
  • you have a moderate, high or very high risk of your cancer coming back – your doctor can tell you more about this 
  • you have had a CT scan in the last month and you no longer have signs of cancer 
  • you are willing to give a tissue sample of your cancer taken when you had surgery or a biopsy Open a glossary item
  • you are fully active, more or less as you were before your cancer diagnosis (performance status of 0
  • your liver is working normally (Child-Pugh score A)
  • you have, or have had, liver infection with the hepatitis C virus and you have finished treatment for it more than 4 weeks ago 
  • you have hepatitis B that is controlled  
  • you have satisfactory blood test results 
  • you are at least 18 years old 
  • you are willing to use reliable contraception during treatment and for up to 4 months afterwards if there is any possibility that you or your partner could become pregnant 

Who can’t take part

Cancer related
You cannot join this trial if any of these apply. You:

  • have had embolisation or chemoembolisation, hepatic artery infusion  Open a glossary itemor stereotactic body radiotherapy (SBRT)
  • still have side effects from your previous cancer treatment  
  • have had pembrolizumab or any other similar drug 
  • have had treatment that reached your whole body (systemic) for liver cancer
  • are currently having any treatment for liver cancer such as radiotherapy, chemotherapy or an investigational treatment
  • have had another cancer in the past 3 years unless it was non melanoma skin cancer or carcinoma in situ  Open a glossary itemof the cervix and breast that has been successfully treated 

Medical conditions
You cannot join this trial if any of these apply. You:

  • are taking part in another clinical trial or have taken part in a trial looking at a new drug or device in the last month 
  • have had bleeding from swollen veins in the food pipe or stomach (oesophageal or stomach varices) in the last 6 months 
  • have a build up of fluid in your tummy (ascites) 
  • have problems with your brain (encephalopathy Open a glossary item) caused by the liver disease
  • have or have had lung problems such as pneumonitis Open a glossary item
  • have an autoimmune disease Open a glossary item that needed treatment that reached your whole body in the past 2 years unless it was treatment to replace something that the body makes such as thyroxine or insulin 
  • take or have taken drugs that damp down your immune system such as steroids Open a glossary item in the past week unless it was a very small dose 
  • have an active infection that needs antibiotics that reach your whole body
  • have both active hepatitis B and hepatitis C – your doctor can tell you more about this 
  • have or have had HIV 
  • have active tuberculosis 
  • have any other serious medical condition or mental health problem that the trial team think could affect you taking part 
  • take an amount of drugs or alcohol that is a concern for your doctor 

Other
You cannot join this trial if any of these apply. You:

  • are pregnant or breastfeeding  
  • have had a live vaccine in the last month 
  • are sensitive to pembrolizumab or anything it contains 

Trial design

This is an international phase 3 trial. Researchers hope that around 950 people worldwide and 27 people from the UK will agree to take part.

It is a randomised trial. Everyone taking part is put into 1 of the following groups by computer:

  • pembrolizumab
  • dummy drug

Neither you nor your doctor can choose which treatment you have. And neither you nor your doctor will know which treatment you are having. This is a double blind trial. 

You have pembrolizumab or dummy drug as a drip into your bloodstream (intravenously). It takes about 30 minutes to have pembrolizumab each time. 

You continue to have treatment for as long as it is helping you and the side effects aren’t too bad. You have up to 17 treatments of pembrolizumab, taking about a year in total. 

Quality of life 
Everybody taking part completes quality of life questionnaires before the start of treatment and:

  • every 3 weeks during treatment
  • at the end of treatment 
  • a month after finishing treatment 
  • every 3 months after a year
  • then every 6 months after 2 years 
  • and then every year until year 5

The questionnaires ask about how you have been feeling and what side effects you have had. 

Blood tests
You have extra blood tests as part of this trial. You have them before the start of treatment and then:

  • every 3 weeks during treatment
  • at the end of treatment
  • at set times during your follow up 

Researchers want to:

  • look of certain proteins (biomarkers Open a glossary item) that can help to tell how well the treatment is working
  • look at the cancer DNA Open a glossary item

Tissue sample
The trial team will ask to use a tissue sample of your cancer taken when you had surgery or a biopsy. Researchers want to learn more about how the treatment affects the cancer. 

Poo (stool) sample
The trial team might ask you to give a poo sample before the start of treatment and then:

  • 3 weeks after the start of treatment
  • 12 weeks after the start of treatment
  • at the end of treatment 

You don’t have to agree to give poo samples if you don’t want to. You can still take part in this trial. 

Hospital visits

You see a doctor and have some tests before taking part. These tests might include:

  • a physical examination
  • a CT scan or MRI scan
  • heart trace (ECG Open a glossary item
  • an endoscopy Open a glossary item
  • blood tests
  • urine test 

During treatment, you see the trial team every 3 weeks. You have blood tests and a physical examination every time you see them. You also have a CT scan or MRI scan every 12 weeks for a year. 

When you finish treatment, you see the trial team after a month. You then see the trial team:

  • every 3 months for 3 years
  • then every 6 months for 2 years
  • then every year for 2 years

After 7 years, the trial team will call you every 3 months to check how you are. 

Side effects

The trial team monitor you during treatment and afterwards. You have a phone number to call them if you are worried about anything. The team will tell you about all the possible side effects before you start the treatment. 

Pembrolizumab affects the immune system. This may cause inflammation in different parts of the body which can cause serious side effects. Side effects can happen during treatment or some months after treatment has finished. Some side effects can be life threatening. 

The most common side effects of pembrolizumab are:

  • skin rashes, itching and changes to your skin colour
  • loose or watery poo (diarrhoea)
  • cough
  • pain in your joints, back and tummy (abdomen)
  • high temperature (fever) 
  • low levels of thyroid hormones in your body causing tiredness, weight gain and feeling cold 
  • low levels of salts in your body which can cause muscle cramps and feeling sick

We have more information about the possible side effects of pembrolizumab

Location

Belfast
Cambridge
Coventry
Glasgow
Leeds
London
Nottingham
Wirral

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Daniel Palmer

Supported by

Merck Sharp & Dohme

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

16404

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think